Discovery may hike stem cell transplants.

abstract：UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...

journal_title：Cancer discovery

authors： Vilar E,Tabernero J

更新日期：2013-05-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors and extracellular matrix components, and have been implicated in...

journal_title：Cancer discovery

authors： Biffi G,Oni TE,Spielman B,Hao Y,Elyada E,Park Y,Preall J,Tuveson DA

更新日期：2019-02-01 00:00:00

abstract：:Critically short telomeres activate cellular senescence or apoptosis, as mediated by the tumor suppressor p53, but in the absence of this checkpoint response, telomere dysfunction engenders chromosomal aberrations and cancer. Here, analysis of p53-regulated genes activated in the setting of telomere dysfunction identi...

journal_title：Cancer discovery

authors： Zhang Y,Shin SJ,Liu D,Ivanova E,Foerster F,Ying H,Zheng H,Xiao Y,Chen Z,Protopopov A,Depinho RA,Paik JH

更新日期：2013-07-01 00:00:00

abstract：:A recent study investigated the mechanisms underlying the interaction between olaparib and cediranib in non-BRCA-mutant ovarian cancer. Cediranib may confer sensitivity to olaparib by increasing tumor hypoxia and inhibiting platelet-derived growth factor receptor, which reduces BRCA1/2 and RAD51 expression, thus decre...

journal_title：Cancer discovery

authors：

更新日期：2019-08-01 00:00:00

abstract：:In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly occurs, and ex vivo models support that some of these bacteria can trigger host transcriptomic signatures associated with carcinogenesis. Here, we show that this lower airway dysbiotic signature was more prevalent in the stage IIIB...

journal_title：Cancer discovery

authors： Tsay JJ,Wu BG,Sulaiman I,Gershner K,Schluger R,Li Y,Yie TA,Meyn P,Olsen E,Perez L,Franca B,Carpenito J,Iizumi T,El-Ashmawy M,Badri M,Morton JT,Shen N,He L,Michaud G,Rafeq S,Bessich JL,Smith RL,Sauthoff H,Fel

更新日期：2020-11-11 00:00:00

abstract：:Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...

journal_title：Cancer discovery

authors： Koppikar P,Bromberg J

更新日期：2012-08-01 00:00:00

abstract：:Spliceosome inhibitors induced mRNA missplicing, retaining introns that formed double-stranded RNA. ...

journal_title：Cancer discovery

authors：

更新日期：2021-01-22 00:00:00

abstract：:Researchers have identified a new compound, OTS964, that blocks cytokinesis. Injections of the compound eliminated human lung tumors that had been transplanted into mice. Clinical trials of OTS964 may start next year. ...

journal_title：Cancer discovery

authors：

更新日期：2015-01-01 00:00:00

abstract：:Residual acute myeloid leukemia (AML) cells required bone marrow stromal cell-derived aspartate. ...

journal_title：Cancer discovery

authors：

更新日期：2020-10-01 00:00:00

abstract：:The FDA granted accelerated approval to palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women who have not yet received endocrine-based therapy. Palbociclib is the first cell cycle-targeting CDK 4/6 inhibitor to reach the market. ...

journal_title：Cancer discovery

authors：

更新日期：2015-04-01 00:00:00

abstract：:The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...

journal_title：Cancer discovery

authors：

更新日期：2018-06-01 00:00:00

abstract：:Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression...

journal_title：Cancer discovery

authors： Sen T,Rodriguez BL,Chen L,Corte CMD,Morikawa N,Fujimoto J,Cristea S,Nguyen T,Diao L,Li L,Fan Y,Yang Y,Wang J,Glisson BS,Wistuba II,Sage J,Heymach JV,Gibbons DL,Byers LA

更新日期：2019-05-01 00:00:00

abstract：:CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples. We conducted paired baseline and end-of-treatment circulating tumor DNA seq...

journal_title：Cancer discovery

authors： O'Leary B,Cutts RJ,Liu Y,Hrebien S,Huang X,Fenwick K,André F,Loibl S,Loi S,Garcia-Murillas I,Cristofanilli M,Huang Bartlett C,Turner NC

更新日期：2018-11-01 00:00:00

abstract：UNLABELLED:Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-50...

journal_title：Cancer discovery

authors： Joseph JD,Lu N,Qian J,Sensintaffar J,Shao G,Brigham D,Moon M,Maneval EC,Chen I,Darimont B,Hager JH

更新日期：2013-09-01 00:00:00

abstract：:Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tu...

journal_title：Cancer discovery

authors： Das RK,Vernau L,Grupp SA,Barrett DM

更新日期：2019-04-01 00:00:00

abstract：:We performed cytosine methylation sequencing on genetically diverse patients with acute myeloid leukemia (AML) and found leukemic DNA methylation patterning is primarily driven by nonpromoter regulatory elements and CpG shores. Enhancers displayed stronger differential methylation than promoters, consisting predominan...

journal_title：Cancer discovery

authors： Glass JL,Hassane D,Wouters BJ,Kunimoto H,Avellino R,Garrett-Bakelman FE,Guryanova OA,Bowman R,Redlich S,Intlekofer AM,Meydan C,Qin T,Fall M,Alonso A,Guzman ML,Valk PJM,Thompson CB,Levine R,Elemento O,Delwel R,Meln

更新日期：2017-08-01 00:00:00

abstract：:The DREAM challenge is a community effort to assess current capabilities in systems biology. Two recent challenges focus on cancer cell drug sensitivity and drug synergism, and highlight strengths and weaknesses of current approaches. ...

journal_title：Cancer discovery

authors： Altman RB

更新日期：2015-03-01 00:00:00

abstract：:Accelerated review and greater understanding of tumor biology speed targeted treatments to patients. ...

journal_title：Cancer discovery

authors： Rose S

更新日期：2011-10-01 00:00:00

abstract：:The combination of the antibody-drug conjugate ado-trastuzumab emtansine, or T-DM1, plus pertuzumab given prior to surgery outperformed standard therapy in women with HER2-positive breast cancer enrolled in the I-SPY 2 trial. The results, reported at the American Association for Cancer Research Annual Meeting 2016, su...

journal_title：Cancer discovery

authors：

更新日期：2016-06-01 00:00:00

abstract：UNLABELLED:Recent proteomic data have uncovered an interdependence of PI3K and STAT3. In PI3K-tranformed murine cells, STAT3 is phosphorylated on Y705 and activated in a PI3K-dependent manner. Dominant negative STAT3 interferes with PI3K-induced oncogenic transformation. Phosphorylation of STAT3 in PI3K-transformed mur...

journal_title：Cancer discovery

authors： Vogt PK,Hart JR

更新日期：2011-11-01 00:00:00

abstract：:Ionizing irradiation and PD-L1 blockade synergistically enhance antitumor immunity. ...

journal_title：Cancer discovery

authors：

更新日期：2014-03-01 00:00:00

abstract：:The California Institute of Quantitative Biosciences offers incubators and other programs that aim to close the gap between discovery and commercialization in biotechnology. ...

journal_title：Cancer discovery

authors：

更新日期：2012-12-01 00:00:00

abstract：:A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. IMMU-132 is well tolerated, causing fewer and more manageable side effects than irinote...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or o...

journal_title：Cancer discovery

authors：

更新日期：2016-12-01 00:00:00

abstract：:In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vo...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：:53BP1 requires RIF1 to block 5' end resection required for homologous recombination. ...

journal_title：Cancer discovery

authors：

更新日期：2013-03-01 00:00:00

abstract：:The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data. ...

journal_title：Cancer discovery

authors：

更新日期：2019-09-01 00:00:00

abstract：:Ubiquitin-specific protease 2a, a deubiquitinating enzyme, elevates MYC levels in prostate cancer cells via its stabilization of MDM2, undermining p53 regulation of microRNAs that target MYC mRNA. ...

journal_title：Cancer discovery

authors： Nelson WG,De Marzo AM,Yegnasubramanian S

更新日期：2012-03-01 00:00:00

abstract：:Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

journal_title：Cancer discovery

authors： Dey P,Kimmelman AC,DePinho RA

更新日期：2021-01-27 00:00:00

abstract：:Amid concerns over the spread of COVID-19, oncology practices have "gone virtual," with video appointments scheduled for any service that does not require diagnostic testing or treatment. ...

journal_title：Cancer discovery

authors：

更新日期：2020-06-01 00:00:00